Skip to main content

Table 4 Mean IOP lowering agents in different groups of glaucoma at all examination time points

From: Outcome of a single XEN microstent implant for glaucoma patients with different types of glaucoma

 

baseline

2 days

1 month

3 months

6 months

12 months

p=

complete group

2.6 ± 1.2

0.1 ± 0.5

0.8 ± 1.4

1.0 ± 1.4

0.9 ± 1.4

0.8 ± 1.3

< 0.01

POAG

2.5 ± 1.2

0.1 ± 0.5

0.7 ± 1.4

0.9 ± 1.4

0.9 ± 1.4

0.8 ± 1.3

< 0.01

NTG

2.6 ± 0.9

0 ± 0

0.7 ± 1.2

0.7 ± 1.0

0.3 ± 0.6

0.6 ± 0.9

< 0.05

PEX

2.9 ± 1.2

0.1 ± 0.4

0.9 ± 1.4

1.1 ± 1.4

0.9 ± 1.4

1.0 ± 1.3

< 0.01

secondary glaucoma

2.6 ± 0.9

0 ± 0

0.9 ± 1.8

0.8 ± 1.5

0.5 ± 1.0

0.6 ± 1.5

< 0.01

  1. Examination values for the number of applied IOP-lowering agents at the beginning of the treatment as well as for all follow-ups after XEN implantation for the whole treated group of eyes and the four subgroups of the different glaucoma types. The P-values given represent the comparison between the baseline and 12-month results for each group